ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) reports the following transactions:
| 1. | Details of the person discharging managerial responsibility / person closely associated | ||
| a) | Name | Søren Daniel Niegel | |
| 2. | Reason for the notification | ||
| a) | Position/status | Member of the Board of Management | |
| b) | Initial notification/ amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | ALK-Abelló A/S | |
| b) | LEI | 529900SGCREUZCZ7P020 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument: (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Shares DK0060027142 | |
| b) | Nature of the transaction | Sale | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 2,425 | 2,619 | ||
| d) | Aggregated information - Aggregated volume - Price | 2,619 DKK 6,352,162 | |
| e) | Date of the transaction | 2021-03-09 | |
| f) | Place of the transaction | Nasdaq Copenhagen | |
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ALK Abello19.12.2025 22:46:46 CET | Press release
Major shareholder announcement
ALK Abello19.12.2025 22:46:46 CET | Pressemeddelelse
Storaktionærmeddelelse
Zealand Pharma19.12.2025 22:00:00 CET | Press release
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Boehringer Ingelheim Limited19.12.2025 21:10:00 CET | Press release
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Novartis Pharma AG19.12.2025 20:30:06 CET | Press release
Novartis and US government reach agreement on lowering drug prices in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
